Evaluation Of Nonsurgical Treatment Of Deep Periodontal Pockets (7-10mm) Using AIRFLOW® Prophylaxis Master Device With Erythritol Powder vs Conventional Instrumentation

Launched by CAIRO UNIVERSITY · Jun 29, 2024

Keywords

ClinConnect Summary

This clinical trial is investigating a new way to treat deep gum pockets (areas where the gums have pulled away from the teeth) that are between 7 to 10 millimeters deep, which can occur in people with periodontitis—a serious gum disease. The study compares a special device called the AIRFLOW® Prophylaxis Master, which uses a powder made from erythritol, to traditional dental tools for cleaning these pockets. Researchers want to see how well each method works in reducing gum bleeding, improving gum attachment to teeth, and overall patient satisfaction, as well as looking at factors like treatment time and costs.

To participate in this trial, individuals must be between the ages of 16 and 80, have at least 20 teeth, and be diagnosed with periodontitis with at least one deep pocket. Those who are generally healthy and can attend follow-up appointments may qualify. However, pregnant or breastfeeding women, individuals with certain health conditions like diabetes or severe respiratory issues, and those with significant gum inflammation are not eligible. Participants can expect a thorough evaluation of their gum health and will receive treatment aimed at improving their condition, with the hope of achieving better results and a more comfortable experience than traditional methods.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Systemically healthy patients.
• • Patients with an age range between 16 to 80 years.
• • Patients have a minimum of 20 teeth.
• • Periodontitis patients with at least one residual pocket with a probing depth ranging from 7 to 10 mm.
• • Cooperative patients able and willing to come for follow up appointments.
• Exclusion Criteria:
• • Pregnant and lactation females.
• • Patients reporting systemic conditions (eg: diabetes).
• • Patients with severe or unstable upper respiratory tract infections, chronic bronchitis/asthma.
• • Patients with severe inflammation and/or osteonecrosis.